Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS) in patients aged between 10 and 17 years old, marking the availability of the first and only oral disease-modifying treatment for that age group in this indication.
![Zonder mens geen merk: waarom AI nooit merkvertrouwen kan automatiseren [onderzoek]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/11/206-80x60.jpg)
